Author:
Walker Douglas,Lue Lih-Fen
Reference70 articles.
1. Han X, He G. Toward a rational design to regulate beta-amyloid fibrillation for Alzheimer’s disease treatment. ACS Chemical Neuroscience. 2018;9:198-210. DOI: 1021/acsche-mneuro.7b00477
2. Prati F, Bottegoni G, Bolognesi ML, Cavalli A. BACE-1 inhibitors: From recent single-target molecules to multitarget compounds for Alzheimer’s disease. Journal of Medicinal Chemistry. 2017;10. DOI: 1021/acs.jmedchem.7b00393
3. Das S, Basu S. Multi-targeting strategies for Alzheimer’s disease therapeutics: Pros and cons. Current Topics in Medicinal Chemistry. 2017;17:3017-3061. DOI: 10.2174/1568026617666170707130652
4. Nesi G, Sestito S, Digiacomo M, Rapposelli S. Oxidative stress, mitochondrial abnormalities and proteins deposition: Multitarget approaches in Alzheimer’s disease. Current Topics in Medicinal Chemistry. 2017;17:3062-3079. DOI: 10.2174/1568026617666170607114232
5. Cascella M, Bimonte S, Muzio MR, Schiavone V, Cuomo A. The efficacy of epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: An overview of pre-clinical studies and translational perspectives in clinical practice. Infectious Agents and Cancer. 2017;12:36. DOI: 10.2174/1568026617666170607114232